The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here is one stock where Wall Street’s excitement appears well-founded and two where analysts may be overlooking some important risks.

Two Stocks to Sell:

Omnicell (OMCL)

Consensus Price Target: $54.14 (64.9% implied return)

Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ:OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency.

Why Do We Think OMCL Will Underperform?

1. Sales tumbled by 7.4% annually over the last two years, showing market trends are working against its favor during this cycle

2. Earnings per share fell by 9.6% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable

3. Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned

Omnicell’s stock price of $30.76 implies a valuation ratio of 17.2x forward price-to-earnings. If you’re considering OMCL for your portfolio, see our FREE research report to learn more .

ANI Pharmaceuticals (ANIP)

Consensus Price Target: $78.67 (17.3% implied return)

With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ:ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.

Why Does ANIP Fall Short?

1. Smaller revenue base of $614.4 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy

2. Performance over the past five years was negatively impacted by new share issuances as its earnings per share were flat while its revenue grew

3. Negative returns on capital show management lost money while trying to expand the business

At $69.82 per share, ANI Pharmaceuticals trades at 13.2x forward price-to-earnings. Read our free research report to see why you should think twice about including ANIP in your portfolio, it’s free .

One Stock to Buy:

Tecnoglass (TGLS)

Consensus Price Target: $89.67 (16.2% implied return)